Clearway Energyの空売り状況は、投資家がClearway Energyの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Clearway Energy (NYSE:CWEN) 株価情報, 空売り情報

Clearway Energy

Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and owner of modern, sustainable and long-term contracted assets across North America. The company segments its operations into Flexible Generation, renewables and Corporate divisions.

Clearway Energy, Inc. Class C Common Stock

Clearway Energy Inc

Clearway Energy, Inc. Class A Common Stock

News

TECX

Tectonic Therapeutic Added To Russell 3000 Index

Revolution Medicines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVMD#NASDAQ">RVMD</a>), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>), a biopharmaceutical oncology company focused on patient-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs, today announced the companies have entered into a clinical collaboration in multiple solid tumor settings to evaluate the safety and efficacy of each of Revolution Medicines' clinical-stage RAS(ON) inhibitors, including the multi-selective inhibitor daraxonrasib (RMC-6236), G12D-selective inhibitor zoldonrasib (RMC-9805) and G12C-selective inhibitor elironrasib (RMC-6291), in combination with Summit Therapeutics' ivonescimab, a PD-1 / VEGF bispecific antibody.
The clinical collaboration aims to evaluate these combinations across three priority tumor types including RAS mutant non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC). Under the terms of the agreement, Summit Therapeutics will supply ivonescimab for clinical research and Revolution Medicines will be the study sponsor. Each company will retain commercial rights to their respective compounds, and the agreement is mutually non-exclusive.

RVMD

SMMT

Revolution Medicines And Summit Therapeutics Collaborate In Multiple Solid Tumor Settings To Evaluate Safety And Efficacy Of Each Of Revolution Medicines' Clinical-Stage RAS(ON) Inhibitors With Summit's Ivonescimab

Takeda Announces FDA Approval Of GAMMAGARD LIQUID ERC

Billionaire entrepreneur&nbsp;Mark Cuban&nbsp;has voiced his concerns over the manipulative practices of insurance companies, suggesting a need for radical changes in the healthcare sector.
What Happened: Cuban, in a post on X on Sunday, criticized insurance companies for designing plans with unaffordable deductibles. He explained that when plan holders can&#8217;t afford these deductibles, they avoid seeking care, allowing insurance companies to pocket the premiums without covering any healthcare costs.
He also highlighted how hospitals bear the financial burden when patients can&#8217;t pay, leading to inflated fees to compensate for these losses.
His post was a response to Senator&nbsp;Josh Hawley&#8216;s post, which questioned the ethics of insurance companies consulting with firms like McKinsey to design programs that exploit policyholders.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">It&#39;s worse than you know. Ins comps design plans with deductibles they know the plan holder can&#39;t afford. If the customer can never afford the deductible, they don&#39;t get care and the ins comp never has to pay for anything. They just keep the premium. If the plan holder… <a href="https://t.co/63WW363CDG">https://t.co/63WW363CDG</a>
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1939395432368800178?ref_src=twsrc%5Etfw">June 29, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Cuban suggested that Sen. Josh Hawley &#8220;freak them out and change the game&#8221;.
The Cost Plus Drugs Founder pitched a tough new proposal targeting insurance companies: Firstly, if an insurer or its subsidiary is fined by the government, it would face increasing bans from doing business with HHS—1 year for the first fine, 3 years for the second, and 5 years for the third.
Secondly, to work with the government or get plan approvals, insurers would have to publicly disclose their entire general ledger, including all subsidiary entries.
&#8220;If you got nothing to hide, hide nothing,&#8221; added Cuban,
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/tech/25/06/46161059/apple-has-the-potential-to-crush-metas-ray-ban-smart-glasses-says-ming-chi-kuo-but-the-tech-giant-ha" target="_blank" rel="noreferrer noopener">Apple Has the Potential To Crush Meta&#8217;s Ray-Ban Smart Glasses, Says Ming-Chi Kuo, But The Tech Giant Has Been &#8216;Surprisingly Slow&#8217;</a>
Why It Matters:&nbsp;Cuban&#8217;s comments come in the wake of his recent proposal to eliminate traditional insurance premiums and introduce transparent pricing in the healthcare sector. His <a href="https://www.benzinga.com/markets/25/06/45992387/mark-cuban-floats-bold-healthcare-plan-zero-premiums-to-insurance-companies-with-a-cash-pay-revoluti">proposal</a>, was sparked by increasing frustration over insurance clawbacks and rising costs.
Even previously, Cuban <a href="https://www.benzinga.com/news/topics/25/05/45711157/mark-cuban-says-taking-low-premium-high-deductible-plans-is-great-for-insurance-companies-you-know-who-its-not-good-for-you-guys">criticized </a>insurance companies for designing plans with low premiums and high deductibles, a strategy he believes is beneficial for insurance companies but detrimental to patients. In another instance, Cuban called<a href="https://www.benzinga.com/25/05/45458113/mark-cuban-blasts-health-insurance-companies-as-the-worst-of-the-worst-says-it-should-be-criminal-to-charge-5k-deductibles-to-people-making-25k"> </a>the <a href="https://www.benzinga.com/25/05/45458113/mark-cuban-blasts-health-insurance-companies-as-the-worst-of-the-worst-says-it-should-be-criminal-to-charge-5k-deductibles-to-people-making-25k">practice </a>of charging exorbitant deductibles to low-income individuals a criminal act.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://www.benzinga.com/personal-finance/tax/25/06/46012776/brace-for-higher-healthcare-premiums-in-2026-as-insurers-blame-trumps-tariffs-in-filings-to-regulators-report">Brace For Higher Healthcare Premiums In 2026 As Insurers Blame Trump&#8217;s Tariffs In Filings To Regulators: Report</a> </li>
</ul>
<ol class="wp-block-list">
<li></li>
</ol>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Mark Cuban Slams Insurers Over High Deductibles, Urges Josh Hawley To 'Change The Game' With Two-Part Plan

OPAL

OPAL Fuels Added To Russell 3000 Index

ACNT

Ascent Industries Joins Russell 2000 Index, Effective June 30, 2025, As Part Of 2025 Russell Indexes Reconstitution

On June 28, his 54th birthday, Elon Musk didn't post celebratory photos or <a href="https://www.benzinga.com/topic/elon-musk">launch a new product.</a>
Instead, he launched another blistering denunciation of President Donald Trump's sweeping tax and spending bill, calling it <a href="https://www.benzinga.com/news/politics/25/06/46159125/elon-musk-calls-trumps-megabill-political-suicide-says-it-is-utterly-insane-and-destructive-will-destroy-millions-of-jobs-in-america">"utterly insane and destructive"</a> in a post on X (formerly Twitter)—an attack that reignited a political feud and underscored a deeper ideological rift between two of the most influential figures in American public life.
The legislation in question, nicknamed the <a href="https://www.benzinga.com/news/politics/25/06/46159430/trumps-major-bill-advances-in-senate-amid-late-night-vote-salt-provision-compromise-stirs-controversy">"Big, Beautiful Bill"</a> by the Trump administration, is a nearly 1,000-page proposal that combines deep tax cuts with significant spending reductions and industry-specific subsidies. The bill, which passed the House by a narrow margin in May, is now under intense scrutiny in the Senate, where Republican leaders are racing to meet Trump's self-imposed July 4 deadline.
<ul class="wp-block-list">
<li>Read More: <a href="https://www.benzinga.com/news/education/25/06/46157568/happy-birthday-elon-musk-54-facts-and-figures-about-tesla-spacex-ceo-on-his-54th-birthday">54 Things You Might Not Know About Elon Musk</a></li>
</ul>
The Tesla and SpaceX CEO&#8217;s criticism wasn't subtle. "The latest Senate draft bill will destroy millions of jobs in America and cause immense strategic harm to our country," he wrote in an X post on June 28. "It gives handouts to industries of the past while severely damaging industries of the future".
His comments came just hours before the Senate was scheduled to vote on whether to open debate on the bill. Musk, who previously served as head of the now-defunct Department of Government Efficiency (DOGE), has been increasingly vocal in his opposition since leaving the administration in May.
Musk's latest broadside wasn&#8217;t a one-off outburst. It was the culmination of a month-long escalation that began on June 3, when Musk first labeled the legislation a <a href="https://www.benzinga.com/news/politics/25/06/45757029/elon-musk-slams-congressional-spending-bill-as-a-disgusting-abomination">"disgusting abomination"</a>. What followed was a <a href="https://www.benzinga.com/news/politics/25/06/45800612/trump-says-musk-has-trump-derangement-syndrome-as-battle-over-bill-heats-up-had-a-great-relationship-dont-know-if-we-will-anymore">public unraveling of the Musk-Trump alliance</a>, complete with televised rebukes, social media barbs, and threats to sever political and financial ties.
But beyond the spectacle lies a more consequential question: What does Musk's opposition signal about the future of U.S. economic policy—and the fragile coalition behind it?
What's In The Big, Beautiful Bill?
The legislation combines sweeping tax cuts with deep spending reductions and targeted subsidies for fossil fuels, defense, and border enforcement. It also raises the debt ceiling by $5 trillion—the largest single increase in U.S. history.
While the bill passed the House in May, it has faced turbulence in the Senate, where moderate Republicans have balked at its impact on the deficit and the rollback of clean energy incentives. Musk's intervention has only intensified that pressure.
Musk's critique aligns with concerns raised by economists and industry leaders. Jesse Jenkins, an energy systems engineer at Princeton, called the bill's energy provisions "truly so bad," noting that automakers, utilities, and manufacturers alike oppose them. The Joint Committee on Taxation estimates the bill's tax provisions alone would reduce federal revenue by more than $4 trillion over the next decade.
Read More: <a href="https://www.benzinga.com/news/politics/25/06/46160881/bernie-sanders-slams-trumps-big-beautiful-bill-as-a-gift-for-billionaires-the-most-dangerous-piece-of-legislation-in-modern-history">Bernie Sanders Slams Trump&#8217;s Bill As &#8216;The Most Dangerous Piece of Legislation In Modern History'</a>
According to the Congressional Budget Office (CBO), the bill would increase the federal deficit by more than $3 trillion over the next decade. While proponents argue that the tax cuts will spur growth, critics—including some within the GOP—warn that the deficit impact could be severe.
Musk Warns Of &#8216;Political Suicide For The Republican Party&#8217;
Musk's opposition isn't limited to clean energy. He has framed the bill as a threat to American competitiveness. "It's political suicide for the Republican Party," he wrote, citing a poll by the Tarrance Group that reportedly shows declining support for the bill among independent voters. By favoring legacy sectors like coal and oil, the outspoken entrepreneur argues, the legislation undermines innovation in AI, space, and advanced manufacturing—areas where the U.S. is competing globally.
The tech billionaire&#8217;s opposition carries weight not just because of his platform—he is the most-followed person on X—but because of his political capital. He was the largest individual donor to Trump's 2024 campaign, contributing over $250 million. He also briefly served as head of the Department of Government Efficiency (DOGE), a role in which he led aggressive reductions in the federal workforce and spending cuts.
What Happens Next?
The Senate remains divided. With a razor-thin Republican majority, any defections could derail the bill. Musk's high-profile opposition may embolden moderate GOP senators who are already uneasy about the bill's deficit impact and industry favoritism.
Meanwhile, Musk's birthday broadside has dominated headlines, shifting attention from legislative details to the broader question of who shapes economic policy in 2025: elected officials or billionaire technocrats.
As the Senate prepares for a critical vote, one thing is clear—Musk's birthday wish wasn't for cake or candles. It was for Congress to kill the bill before, in his words, it kills the economy.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46087914/teslas-europe-sales-slide-for-5th-straight-month-elon-musk-led-ev-giants-market-share-shrinks-to-1-3">Tesla&#8217;s Europe Sales Slide For 5th Straight Month: Elon Musk-led EV Giant&#8217;s Market Share Shrinks To 1.3%</a></li>
</ul>
Photo: Shutterstock

Economics

Elon Musk's Birthday Wish: Kill The Bill Before It Kills The Economy

MDAI

Spectral AI Submits De Novo 510k Marketing Clearance Application To FDA For DeepView System

Seaport Global analyst Jeff Cantwell initiates coverage on Chime Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHYM#NASDAQ">CHYM</a>) with a Buy rating and announces Price Target of $37.

Price Target

Initiation

Analyst Ratings

CHYM

Seaport Global Initiates Coverage On Chime Financial with Buy Rating, Announces Price Target of $37

<ul>
<li>Biofrontera Inc. has signed an agreement to acquire all US assets related to Ameluz&#xAE; and RhodoLED&#xAE; including New Drug Application (NDA) and associated patents from Germany-based Biofrontera AG.</li>
<li>Under their new agreement, the effective royalty rate paid by Biofrontera Inc. will be reduced to 12% (and 15% above revenue of $65 million) of net sales from 25% - 35% of net sales.</li>
<li>This transaction, coupled with an $11 million financing led by existing investors, Rosalind Advisors and AIGH Capital Management LLC, is expected to fund Biofrontera Inc. to profitability.</li>
</ul>

BFRI

Biofrontera Inc. Acquires All US Rights To Ameluz And RhodoLED From Former Parent Co. Biofrontera AG, Coupled With $11M Financing Led Bt Existing Investors; Under New Agreement, Effective Royalty Rate Paid By Co. Will Be Reduced To 12% Of Net Sales

Sound Point Capital Management Appoints Dan Fabian As Global CFO, Succeeding Kevin Gerlitz, Effective Immediately

Ferroglobe Included In Russell 2000 And Russell 3000 Indexes Effective June 30, 2025

Benchmark analyst David Williams reiterates IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) with a Buy and maintains $50 price target.

Reiteration

IONQ

Benchmark Reiterates Buy on IonQ, Maintains $50 Price Target

METC

Ramaco Resources To Release Updated Information Including Prelim. Economics For Its Brook Mine Rare Earth and Critical Minerals Project On Jul. 1 Before 9: 00 a.m. EST

In the preceding three months, 12 analysts have released ratings for Magnite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">11</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $20.5, along with a high estimate of $39.00 and a low estimate of $14.00. Surpassing the previous average price target of $19.00, the current average has increased by 7.89%.
<img src="https://www.benzinga.com/files/images/story/2025/1751284821_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Magnite among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$39.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Eric Martinuzzi</td>
<td>Lake Street</td>
<td>Lowers</td>
<td>Buy</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Announces</td>
<td>Buy</td>
<td>$18.00</td>
<td>-</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Magnite. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Magnite compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Magnite's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Magnite's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MGNI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Magnite analyst ratings.</a>
<h2>Unveiling the Story Behind Magnite</h2>
Magnite Inc is one of the supply-side platform providers, or SSP, in online advertising. The firm generate its revenue from the programmatic sale of CTV ad inventory, from mobile online sites and apps, and the remaining from websites accessed via computer.
<h3>Magnite's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Magnite displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 4.32%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Communication Services sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Magnite's net margin excels beyond industry benchmarks, reaching -6.18%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Magnite's ROE stands out, surpassing industry averages. With an impressive ROE of -1.28%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -0.35%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.83, Magnite adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MGNI

12 Analysts Assess Magnite: What You Need To Know

Vistra Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) is currently in Phase 11 of its 18-phase Adhishthana Cycle. The stock&#8217;s structure remains bullishly intact according to the Adhishthana framework. Here&#8217;s a breakdown of what triggered the move and where the stock is likely headed next.
<h3 class="wp-block-heading">Why Did VST Start Rallying in November 2023?</h3>
According to the Adhishthana Principles, Phases 4 through 8 typically form the Adhishthana Cakra, a bullish arc or channel structure that serves as a preparatory foundation. A breakout in Phase 9 often marks the beginning of a supreme bullish move and initiates what is known as the Himalayan Formation.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="895" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105156/VST-Weekly-Chart-Cakra-Adhishthana.png" alt="Fig.1 VST Cakra Breakout (Source: Adhishthana.com)" class="wp-image-15074" style="width:638px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105156/VST-Weekly-Chart-Cakra-Adhishthana.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105156/VST-Weekly-Chart-Cakra-Adhishthana-300x224.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105156/VST-Weekly-Chart-Cakra-Adhishthana-1024x764.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105156/VST-Weekly-Chart-Cakra-Adhishthana-768x573.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.1 VST Cakra Breakout (Source: Adhishthana.com)</figcaption></figure>
In VST's case, the setup followed the framework precisely. After constructing the Adhishthana Cakra, the stock broke out in Phase 9, rallying by approximately 233%. This breakout was the foundational move that triggered its ongoing ascent and marked the beginning of the Himalayan Formation.
<h3 class="wp-block-heading">VST&#8217;s Phase 10: The Peak Attempt</h3>
During Phase 10, stocks generally make their first attempt at a peak. VST followed suit, hitting a high of $199.84 on the 31st bar of the phase. Although it experienced a brief decline afterward, the stock never breached its Phase 9 mid or low levels, indicating the structure of ascent was still intact.
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">"When analysing the Himālaya move during C10, it is crucial to consider the C9 levels (High/Mid/Low)—if these key levels remain unbroken, the ascent continues." — Adhishthana: The Principles That Govern Wealth, Time &amp; Tragedy
</blockquote>
<h3 class="wp-block-heading">VST&#8217;s Phase 11: Ascent Still Underway</h3>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="882" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105339/VST-Current-Weekly-Phase-Adhishthana-.png" alt="Fig.2 VST's Phases 9, 10 &amp; 11 (Source: Adhishthana.com)" class="wp-image-15075" style="width:480px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105339/VST-Current-Weekly-Phase-Adhishthana-.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105339/VST-Current-Weekly-Phase-Adhishthana--300x221.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105339/VST-Current-Weekly-Phase-Adhishthana--1024x753.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105339/VST-Current-Weekly-Phase-Adhishthana--768x564.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.2 VST&#8217;s Phases 9, 10 &amp; 11 (Source: Adhishthana.com)</figcaption></figure>
With the ascent structure still intact, VST has continued its upward trajectory since entering Phase 11, already gaining 91%. This sustained momentum increases the likelihood that the stock will surpass its previous Phase 10 high of $199.84 during the current phase.
Phase 11 concludes on May 3, 2026, leaving ample room for the stock to form its Himalayan peak. While a peak typically occurs in this phase, in some rare cases where the structure remains firm without a conclusive top, a peak can emerge in Phase 12 instead.
<h3 class="wp-block-heading">Monthly Chart Confirms Bullish Move</h3>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1078" height="818" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105424/VST-Monthly-Phase-2-Chart-Adhishthana.png" alt="Fig.3 VST Monthly Chart (Source: Adhishthana.com)" class="wp-image-15076" style="width:550px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105424/VST-Monthly-Phase-2-Chart-Adhishthana.png 1078w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105424/VST-Monthly-Phase-2-Chart-Adhishthana-300x228.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105424/VST-Monthly-Phase-2-Chart-Adhishthana-1024x777.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105424/VST-Monthly-Phase-2-Chart-Adhishthana-768x583.png 768w" sizes="(max-width: 1078px) 100vw, 1078px" /><figcaption class="wp-element-caption">Fig.3 VST Monthly Chart (Source: Adhishthana.com)</figcaption></figure>
VST began its Buddhi rally on the monthly timeframe on May 1, 2024. Since then, the stock has already appreciated by roughly 192%, once again aligning well with the expectations set by the Adhishthana Principles.
This monthly Phase 2 continues until March 31, 2027, further supporting the view that bullish momentum remains intact for the foreseeable future.
<h3 class="wp-block-heading">Investor Takeaway: Let the Rally &amp; Peak Unfold</h3>
If you currently hold VST in your portfolio, the Adhishthana structure suggests you should continue holding. The stock has not yet formed its peak, and the bullish formation remains active. Any visible signs of a peak will appear only after a clear structural break, which has not occurred yet. Until then, VST appears poised to take out its previous high and continue its ascent.

Equities

Technicals

Opinion

Signals

Trading Ideas

Vistra's Rally Explained: Where Is The Stock Headed Next

D. Boral Capital analyst Jason Kolbert maintains Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) with a Buy and maintains $36 price target.

OMER

D. Boral Capital Maintains Buy on Omeros, Maintains $36 Price Target

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer recommended buying Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>), saying he wants to own more Okta.
On the earnings front, Okta, on May 27, reported first-quarter revenue of $688 million, beating analyst estimates of $680.25 million. The company reported adjusted earnings of 86 cents per share, beating analyst estimates of 77 cents per share.
Cramer said he is not going to trust Nebius Group N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIS#NASDAQ">NBIS</a>).
DA Davidson analyst Alex Platt, on June 16, maintained Nebius Group with a Buy rating and raised the price target from $50 to $55.
Sweetgreen, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) is down 57%, and it is not making money, Cramer said.
Supporting his view, JP Morgan analyst Rahul Krotthapalli, on June 25, maintained Sweetgreen with a Neutral rating and lowered the price target from $20 to $16.
Cramer said Monster Beverage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>) is &#8220;just one smoking hot stock.&#8221;
Lending support to his choice, Wells Fargo analyst Chris Carey, on June 13, maintained Monster Beverage with an Overweight rating and raised the price target from $67 to $70.
Cramer said it's the time to buy McDonald&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>). &#8220;I've been saying that you must own McDonald's here,&#8221; he added.
In an official announcement last Tuesday, McDonald's and Krispy Kreme Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNUT#NASDAQ">DNUT</a>) have decided to part ways. Concerns about profitability led to the termination of this association. Their U.S. doughnut partnership is set to conclude on July 2, 2025. 
Price Action:
<ul class="wp-block-list">
<li>Nebius shares fell 1.4% to settle at $51.84 on Friday.</li>
<li>Sweetgreen shares declined 0.4% to close at $13.59.</li>
<li>McDonald's shares gained 2.1% to settle at $291.55 during the session.</li>
<li>Monster Beverage fell 0.8% to settle at $61.71 on Friday.</li>
<li>Okta shares gained 0.3% to close at $98.43.</li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/46136470/jim-cramer-just-revealed-1-oil-stock-he-actually-wants-to-own">Jim Cramer Just Revealed 1 Oil Stock He Actually Wants To Own</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Markets

Media

DNUT

MNST

NBIS

OKTA

Cramer Praises Monster Beverage As 'Smoking Hot,' Warns Investors About This AI Stock

HPE: 14% &#x7C; <a href="https://www.benzinga.com//node/46165707">Hewlett Packard Enterprise shares are trading higher after the company and Juniper Networks reached an agreement with the U.S. Department of Justice to resolve its lawsuit challenging HPE's acquisition of Juniper, clearing the way for the deal to close.</a>
&nbsp;
VERO: 59% &#x7C; <a href="https://www.benzinga.com//node/46153651">Venus Concept shares are trading higher after Madryn Asset Management increased its stake in the company to 85.5%.</a>
&nbsp;
WBUY: 64% &#x7C; <a href="https://www.benzinga.com//node/46165253">Webuy Global Partners With Coinbase Commerce To Launch Stablecoin Payment Option For Global Travel And E-Commerce Offerings</a>

Movers

VERO

WBUY

Market-Moving News for June 30th

First Orally Active Fatty Acid Binding Protein 5 Inhibitor Evaluated in Humans
First-in-Class Approach Targets Unmet Need in Multibillion-Dollar Pain Management Market
SOLANA BEACH, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced favorable results from its first-in-human study evaluating ART26.12, a novel inhibitor of Fatty Acid Binding Protein 5 (FABP5). The results affirm the promising safety and pharmacokinetic (PK) profile previously observed in preclinical studies.
Inhibiting FABP5 represents a unique mechanism of action with ART26.12 standing out as a first-in-class candidate in the field of pain management. The Phase 1 Single Ascending Dose (SAD) study was designed to assess the safety, tolerability, and pharmacokinetics of ART26.12 in healthy volunteers. The SAD study enrolled 49 subjects.
The key findings include:
<ul>
<li>Excellent Safety Results: All adverse events (AEs) were mild, transient, and self-resolving. No drug-related AEs were observed in the blinded dataset, and no tolerability issues or safety signals were detected across multiple assessments (vital signs, ECGs, clinical laboratory tests, physical examinations, and visual analogue mood scales).</li>
<li>Predictable PK: Full dose-exposure profiles were successfully explored. Plasma analysis confirmed dose-dependent, linear absorption across the evaluated range.</li>
<li>Therapeutic Window: A wide safety margin was observed between estimated therapeutic plasma concentrations and the highest exposure levels achieved, supporting potential titration for maximum efficacy in future studies.</li>
</ul>

ARTL

Artelo Biosciences Announces Results From Its First-In-Human Study Evaluating ART26.12, Inhibitor Of FABP5; Says Results Affirm Safety And PK Profile Previously Observed In Preclinical Studies

Press Releases

Clearway Energy, Inc. to Report Third Quarter 2024 Financial Results on October 30, 2024

Earnings

Clearway Energy, Inc. Reports Third Quarter 2024 Financial Results

Management

Jennifer Lowry to Join the Board of Directors of TPI Composites, Inc.

Clearway Energy, Inc. Signs Binding Agreement to Acquire 137 MW Wind Project

Clearway Energy, Inc. to Report Fourth Quarter 2024  Financial Results on February 24, 2025

Clearway Energy, Inc. Increases Quarterly Dividend to  $0.4312 per Share

Dividends

Clearway Energy, Inc. Reports Full Year 2024 Financial Results

Clearway Energy, Inc. to Report First Quarter 2025  Financial Results on April 30, 2025

Comments

Clearway Energy

空売り

Clearway Energy (NYSE:CWEN) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル